A new era of service by the AVLS to our HEALTHCARE POLICY AND ADVOCACY BROUGHT TO YOU BY THE AVLS, THE FOUNDATION FOR VENOUS & LYMPHATIC DISEASE, AND OUR VOLUNTEER MEMBERS STEPHEN F. DAUGHERTY, MD, FACS, FAVLS, RVT, RPHS CHAIRMAN, AVLS HEALTHCARE POLICY COMMITTEE
ROBERT WHITE DIRECTOR OF HEALTHCARE POLICY & ADVOCACY, AVLS
• A unified voice representing the specialty of venous and lymphatic medicine • • • • • • •
Engaging with stakeholders- Medicare, FDA, American Medical Association Comments on proposed policies Participation in the AMA CPT process Participation in the AMA Resource-Based Relative Value Update Committee Representation at the AMA House of Delegates where decisions do affect us Representation on the IAC-Vein Center Division Board of Directors Direct engagement with Federal government and Capitol Hill with written comments and personal visits to Capitol Hill and CMS
• Fair reimbursement and patient access for vein care • • • • • •
Putting the physician at the center of the care process The right treatment for each patient Development of Position Statements published on our website regarding the new vein technologies and support of new technologies and payment with multiple payors Harnessing data to prove the care we provide is appropriate and improves outcomes for patients supports our advocacy for FAIR payment Partnering with Medicare and other payors to improve medical coverage policies In-person meetings with CMS Medicare leadership and representing the AVLS on Medicare Carrier Advisory Committees and at open carrier policy meetings (First Coast Services Organization, Novitas, Palmetto)
• Leveraging our AVLS Guidelines Committee to ensure care standards support our Advocacy communications with other venous stakeholders • The future will be determined by what we do NOW to address the many challenges ahead. • • • • •
Our current national payment and care delivery system will change - we need to understand how. Fee for Service is going away - our future must be about quality of care and value. Data informs all that we do - it helps us improve what we do, and it will support payment for value. The AVLS PRO 2.0 Registry is central to the next decade. We must harness our data. Venous & Lymphatic Medicine is our contribution to mankind, and we are all stronger with AVLS as our voice. We must continue to increase our efforts on behalf of our patients and our profession.
8
